StockNews.AI
JAGX
StockNews.AI
133 days

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

1. Jaguar's Gelclair targets oral mucositis, expanding cancer care focus. 2. Exhibition at ONS Congress showcases ongoing commercialization efforts.

3m saved
Insight
Article

FAQ

Why Bullish?

The expansion into cancer-related supportive care with Gelclair adds a promising revenue stream, reminiscent of similar successful oncology products that boosted their companies' stocks.

How important is it?

This event marks a crucial strategic shift for Jaguar, indicating potential long-term revenue growth from Gelclair, impacting investor confidence and stock performance.

Why Long Term?

Success in the oncology market typically builds over time as awareness and adoption increase, similar to how other sector players like Gilead have established footholds.

Related Companies

GILDABBVAMGN
Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the 50th anniversary Oncology Nursing Society (ONS) Congress taking place April 9-13, 2025 in Denver, Colorado as part of ongoing commercial activities for Gelclair. "We have expanded our footprint beyond HIV-related supportive care to include cancer-related supportive care, and our recent in-licensing of the FDA-approved oral mucositis product Gelclair is a first building block," said Lisa Conte, Jaguar's president and CEO.

Related News